Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance
- PMID: 17637173
- DOI: 10.1211/jpp.59.6.0007
Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance
Abstract
Methods for prediction of hepatic clearance (CL(H)) in man have been evaluated. A physiologically-based in-vitro to in-vivo (PB-IVIV) method with human unbound fraction in blood (f(u, bl)) and hepatocyte intrinsic clearance (CL(int))-data has a good rationale and appears to give the best predictions (maximum approximately 2-fold errors; < 25% errors for half of CL-predictions; appropriate ranking). Inclusion of an empirical scaling factor is, however, needed, and reasons include the use of cryo-preserved hepatocytes with low activity, and inappropriate CL(int)- and f(u, bl)-estimation methods. Thus, an improvement of this methodology is possible and required. Neglect of f(u, bl) or incorporation of incubation binding does not seem appropriate. When microsome CL(int)-data are used with this approach, the CL(H) is underpredicted by 5- to 9-fold on average, and a 106-fold underprediction (attrition potential) has been observed. The poor performance could probably be related to permeation, binding and low metabolic activity. Inclusion of scaling factors and neglect of f(u, bl) for basic and neutral compounds improve microsome predictions. The performance is, however, still not satisfactory. Allometry incorrectly assumes that the determinants for CL(H) relate to body weight and overpredicts human liver blood flow rate. Consequently, allometric methods have poor predictability. Simple allometry has an average overprediction potential, > 2-fold errors for approximately 1/3 of predictions, and 140-fold underprediction to 5800-fold overprediction (potential safety risk) range. In-silico methodologies are available, but these need further development. Acceptable prediction errors for compounds with low and high CL(H) should be approximately 50 and approximately 10%, respectively. In conclusion, it is recommended that PB-IVIV with human hepatocyte CL(int) and f(u, bl) is applied and improved, limits for acceptable errors are decreased, and that animal CL(H)-studies and allometry are avoided.
Similar articles
-
Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.J Pharm Pharmacol. 2007 Oct;59(10):1427-31. doi: 10.1211/jpp.59.10.0014. J Pharm Pharmacol. 2007. PMID: 17910819
-
Prediction of human pharmacokinetics - renal metabolic and excretion clearance.J Pharm Pharmacol. 2007 Nov;59(11):1463-71. doi: 10.1211/jpp.59.11.0002. J Pharm Pharmacol. 2007. PMID: 17976256 Review.
-
Prediction of human pharmacokinetics--gut-wall metabolism.J Pharm Pharmacol. 2007 Oct;59(10):1335-43. doi: 10.1211/jpp.59.10.0002. J Pharm Pharmacol. 2007. PMID: 17910807 Review.
-
Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation.J Pharm Pharmacol. 2008 May;60(5):535-42. doi: 10.1211/jpp.60.5.0001. J Pharm Pharmacol. 2008. PMID: 18416932 Review.
-
Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.Drug Metab Dispos. 2001 Oct;29(10):1316-24. Drug Metab Dispos. 2001. PMID: 11560875
Cited by
-
Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction.J Comput Aided Mol Des. 2008 Nov;22(11):843-55. doi: 10.1007/s10822-008-9225-4. Epub 2008 Jun 24. J Comput Aided Mol Des. 2008. PMID: 18574695 Review.
-
Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.Pharm Res. 2015 Jan;32(1):260-74. doi: 10.1007/s11095-014-1460-x. Epub 2014 Jul 22. Pharm Res. 2015. PMID: 25048637
-
Applications of human pharmacokinetic prediction in first-in-human dose estimation.AAPS J. 2012 Jun;14(2):262-81. doi: 10.1208/s12248-012-9332-y. Epub 2012 Mar 10. AAPS J. 2012. PMID: 22407287 Free PMC article. Review.
-
Metabolites in the regulatory risk assessment of pesticides in the EU.Front Toxicol. 2023 Dec 19;5:1304885. doi: 10.3389/ftox.2023.1304885. eCollection 2023. Front Toxicol. 2023. PMID: 38188093 Free PMC article. Review.
-
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Arch Toxicol. 2013 Aug;87(8):1315-530. doi: 10.1007/s00204-013-1078-5. Epub 2013 Aug 23. Arch Toxicol. 2013. PMID: 23974980 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical